Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Liverpool researchers reach major milestone towards creating diagnostic test for prostate cancer

A research team from the University of Liverpool has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.

12 Feb 2016

Scientists propose use of mathematical models to find better treatment for bladder cancer

MIPT scientists together with their colleagues from St. Petersburg and Israel have analyzed more than 500 previously published scientific articles and proposed their own approach to the choice of methods used for the treatment of one of the most common cancers.

11 Feb 2016

Colon cancer patients lacking CDX2 protein more likely to benefit from chemotherapy

Using a new computer science approach, researchers at University of California, San Diego School of Medicine, Columbia University and Stanford University discovered a distinctive molecular feature — a biomarker — that identified colon cancer patients who were most likely to remain disease-free up to five years after surgery.

22 Jan 2016

MDxHealth recognized with 2015 Global Frost & Sullivan Award for Technology Innovation

Based on its recent analysis of the prostate cancer diagnostics market, Frost & Sullivan recognizes MDxHealth with the 2015 Global Frost & Sullivan Award for Technology Innovation. To advance molecular diagnostic tests for urological cancers, MDxHealth supplemented its prostate cancer test, ConfirmMDx, with a urine-based "liquid-biopsy" test called SelectMDx.

21 Jan 2016

Researchers reveal totally new biological mechanism that underlies cancer

In a landmark study, researchers from the Broad Institute and Massachusetts General Hospital reveal a completely new biological mechanism that underlies cancer. By studying brain tumors that carry mutations in the isocitrate dehydrogenase (IDH) genes, the team uncovered some unusual changes in the instructions for how the genome folds up on itself.

13 Jan 2016

Patient's mental health prior to radical cystectomy can influence postoperative outcomes

A patient's mental health prior to surgery can influence postoperative outcomes. Removal of the bladder, or radical cystectomy (RC), is an effective treatment for locally advanced bladder cancer, but complications occur in as many as 66% of patients.

18 Dec 2015

Viralytics announces completion of $28 million placement

Viralytics Limited announces that it has completed a placement of 46,118,270 shares to international and domestic sophisticated or professional investors at an issue price of $0.615 per share to raise $28,362,736.

14 Dec 2015

Personalised peptide vaccination promising in bladder cancer

Metastatic bladder cancer patients who have progressed on first-line platinum-based chemotherapy could derive survival benefits from personalised peptide vaccination, according to phase II trial results.

27 Nov 2015

Novel immunotherapeutic approach could improve outcomes for patients with advanced bladder cancer

Noguchi explained that immunotherapy has emerged recently as a viable and attractive strategy for the treatment of advanced cancer.

18 Nov 2015

Viralytics enters into clinical trial collaboration agreement with MSD

Viralytics Limited announced today that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. (known as MSD outside the United States and Canada) to evaluate the combination of Viralytics' investigational cancer immunotherapy CAVATAK, with MSD's KEYTRUDA, an anti-PD-1 (programmed death receptor-1) therapy.

6 Nov 2015

Urinary biomarkers for bladder cancer diagnosis fall short of mark

Authors of a meta-analysis question the accuracy of urinary biomarkers for diagnosing the initial incidence or recurrence of bladder cancer.

4 Nov 2015

Liposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman

For about the last 25 years, the cardiology group here have been developing a platform technology for both the diagnosis and treatment of atherosclerosis.

From Beckman Coulter Life Sciences - Particle Counting and Characterization 28 Oct 2015

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx immunohistochemistry companion diagnostic.

From Quest Diagnostics 7 Oct 2015

Oxford Gene Technology launches Cytocell FISH probe for bladder cancer

Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched its CE-IVD labelled Cytocell Aquarius® P16/3c/7c/17c Probe Kit, a cost-effective, ready-to-use fluorescence in situ hybridisation (FISH) probe kit for non-invasive detection of bladder cancer — for sale in Europe.

From Oxford Gene Technology 6 Oct 2015

Mycobacterium could be more effective in treating superficial bladder cancer, study finds

Universitat Autònoma de Barcelona researchers have found a mycobacterium that is more effective in treating superficial bladder cancer and does not cause infections, unlike those used up to now.

6 Oct 2015

OncoGenex meets target enrollment in apatorsen Phase 2 trial

OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.

30 Sep 2015

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

An international team of cancer researchers that included UT Southwestern Medical Center physicians announced "game-changing results" using the immunotherapy drug nivolumab to treat certain lung cancers that failed to respond to first-line therapies.

29 Sep 2015

Phase II IMvigor 210 data shows atezolizumab may prevent progression of metastatic urothelial bladder cancer

Data presented today at the 2015 European Cancer Congress (ECC) demonstrates that the investigational immunotherapy atezolizumab may prevent progression of metastatic urothelial bladder cancer (mUBC) in all age groups by 2.1 months.

29 Sep 2015

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.

23 Sep 2015

Study demonstrates effectiveness of new approach to protect humans from infectious disease

There are two common approaches to protecting humans from infectious disease: Targeting pathogens and parasites with medicines like antibiotics, or dealing with the conditions that allow transmission.

8 Sep 2015

Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Liverpool researchers reach major milestone towards creating diagnostic test for prostate cancer

Scientists propose use of mathematical models to find better treatment for bladder cancer

Colon cancer patients lacking CDX2 protein more likely to benefit from chemotherapy

MDxHealth recognized with 2015 Global Frost & Sullivan Award for Technology Innovation

Researchers reveal totally new biological mechanism that underlies cancer

Patient's mental health prior to radical cystectomy can influence postoperative outcomes

Viralytics announces completion of $28 million placement

Personalised peptide vaccination promising in bladder cancer

Novel immunotherapeutic approach could improve outcomes for patients with advanced bladder cancer

Viralytics enters into clinical trial collaboration agreement with MSD

Urinary biomarkers for bladder cancer diagnosis fall short of mark

Liposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Oxford Gene Technology launches Cytocell FISH probe for bladder cancer

Mycobacterium could be more effective in treating superficial bladder cancer, study finds

OncoGenex meets target enrollment in apatorsen Phase 2 trial

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

Phase II IMvigor 210 data shows atezolizumab may prevent progression of metastatic urothelial bladder cancer

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

Study demonstrates effectiveness of new approach to protect humans from infectious disease

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in